Investors at the AVCJ Forum offered optimistic outlooks for 2020 but said tighter deal markets would demand specialization in defensive sectors and a closer watch on valuations.
Looming signs of recession, high levels of dry powder, a lack of clarity around exits, growing competition for deals, and generally waning sentiment were flagged as the top concerns in a panel on the outlook...
Increased climate change awareness on a corporate level is leading to more investment – either direct or through funds – in start-ups that offer mitigation solutions. Asia is a key geography
Healthcare-focused Panacea Venture has led a $40 million Series C round for China’s XWPharma, a neurobiology-focused biotech developer previously known as XW Laboratories.
Kyee Technology, a Chinese digital medical platform has raised RMB430 million ($64 million) in a Series D round led by Tencent Holdings. Other investors include Longmen Capital, Dyee Capital and Royal Sea Capital.
Biocytogen, a Chinese contract research organization (CRO) that provides genetically-modified mice for drug testing, has raised RMB970 million ($143 million) in an extended tranche of Series D funding.